# Antihypertensive Drug Selection Based on Hemodynamic Phenotypes

Study · id `cardio:ct-nct07240909` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07240909](<https://clinicaltrials.gov/study/NCT07240909>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07240909

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.

## Technical summary

Registry record NCT07240909. Randomized; single masking; primary purpose treatment. Start 2026-01 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT07240909, source copy `cardio:ctgov-nct07240909-2025-11-21`, retrieved 2026-10-26)
- Planned start: 2026-01 (anticipated) (ClinicalTrials.gov record NCT07240909, source copy `cardio:ctgov-nct07240909-2025-11-21`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07240909, source copy `cardio:ctgov-nct07240909-2025-11-21`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07240909, source copy `cardio:ctgov-nct07240909-2025-11-21`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07240909-2025-11-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Antihypertensive Drug Selection Based on Hemodynamic Phenotypes
- Acronym: HEMOPHENO
- Condition: Hypertension
- Intervention (Drug): hemodynamics-based individualized antihypertensive therapy
- Intervention (Drug): guideline-based conventional treatment
- Lead sponsor: The Third Xiangya Hospital of Central South University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: The Third Xiangya Hospital of Central South University (`cardio:org-the-third-xiangya-hospital-of-central-south-university`)

## Provenance

Content hash: 679e7358f7d540cf24a92feb76c5780791e4c9f48f6bd675693b37bd0f3ac07d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
